Abstract:

Objective　To explore the effect of Jinsang Sanjie capsules in patients with reflux pharyngitis. Methods　A total of 94 patients with reflux pharyngitis in Qingyang Hospital of Traditional Chinese Medicine from August 2020 to July 2021 were selected for retrospective study. According to different treatment plans, they were divided into a control group and an observation group, with 47 cases in each group. There were 22 males and 25 females in the control group, aged (46.51±8.79) years; there were 19 males and 28 females in the observation group, aged (45.51±7.79) years. The control group was treated with rabeprazole and mosapride, and the observation group was additionally treated with Jinsang Sanjie capsules on the basis of the control group. The total effective rates, clinical symptom scores, serum inflammatory factors levels [interleukin-2 (IL-2), IL-8, and tumor necrosis factor-α (TNF-α)], plasma gastrointestinal hormones levels [vasoactive intestinal peptide (VIP), motilin (MTL), and gastrin (GAS)], and adverse reactions of the two groups were observed. The measurement data were tested by independent sample t test or paired t test and the count data by χ² test. Results　The total effective rate of the observation group was 95.74% (45/47), higher than that of the control group [82.98% (39/47)] (P<0.05). After treatment, the scores of cough, dysphagia, sticky throat, heartburn and acid reflux, and heating in the observation group were (0.51±0.14) points, (0.32±0.17) points, (0.31±0.12) points, (0.42±0.14) points, and (0.61±0.28) points, respectively, lower than those in the control group [(0.66±0.23) points, (0.41±0.22) points, (0.49±0.17) points, (0.71±0.29) points, and (0.81±0.31) points] (all P<0.05). After treatment, the levels of IL-8, TNF-α, and VIP in the observation group were (12.17±1.21) ng/L, (8.31±1.07) ng/L, and (16.88±2.19) ng/L, respectively, lower than those in the control group [(19.31±2.75) ng/L, (13.10±1.26) ng/L, and (20.86±2.31) ng/L], and the levels of IL-2, MTL, and GAS were (8.43±1.96) μg/L, (320.25±46.14) ng/L, and (162.96±23.15) ng/L, respectively, higher than those in the control group [(6.31±1.05) μg/L, (281.29±42.56) ng/L, and (133.57±18.46) ng/L] (all P<0.05). The rate of adverse reactions in the observation group was 4.26% (2/47), and there was no statistically significant difference compared with 8.51% (4/47) in the control group (P>0.05). Conclusion　Jinsang Sanjie capsules combined with rabeprazole and mosapride has a significant effect in the treatment of reflux pharyngitis, which can effectively improve the patients' symptoms and reduce the levels of inflammatory factors.

Key words: Jinsang Sanjie capsules, Mosapride, Rabeprazole, Reflux pharyngitis

摘要： 目的　探究金嗓散结胶囊在反流性咽喉炎患者中的应用效果。方法　选取庆阳市中医医院2020年8月至2021年7月反流性咽喉炎患者94例进行回顾性研究，根据治疗方案不同分为对照组、观察组，各47例。对照组男22例，女25例，年龄（46.51±8.79）岁；观察组男19例，女28例，年龄（45.51±7.79）岁。对照组采用雷贝拉唑、莫沙必利治疗，观察组在对照组基础上加用金嗓散结胶囊口服治疗。观察统计2组治疗总有效率、临床症状积分、血清炎性因子水平［白细胞介素-2（IL-2）、IL-8、肿瘤坏死因子-α（TNF-α）］、血浆胃肠激素水平［血管活性肠肽（VIP）、胃动素（MTL）、胃泌素（GAS）］及不良反应。计量资料组间行独立样本t检验、组内行配对t检验，计数资料行χ²检验。结果　观察组总有效率95.74%（45/47）高于对照组82.98%（39/47）（P<0.05）。治疗后观察组咳嗽、吞咽困难、咽喉黏滞、烧心反酸、暖气积分分别为（0.51±0.14）分、（0.32±0.17）分、（0.31±0.12）分、（0.42±0.14）分、（0.61±0.28）分，均低于对照组的（0.66±0.23）分、（0.41±0.22）分、（0.49±0.17）分、（0.71±0.29）分、（0.81±0.31）分（均P<0.05）。治疗后观察组IL-8、TNF-α、VIP水平分别为（12.17±1.21）ng/L、（8.31±1.07）ng/L、（16.88±2.19）ng/L，均低于对照组（19.31±2.75）ng/L、（13.10±1.26）ng/L、（20.86±2.31）ng/L，IL-2、MTL、GAS水平分别为（8.43±1.96）μg/L、（320.25±46.14）ng/L、（162.96±23.15）ng/L，高于对照组的（6.31±1.05）μg/L、（281.29±42.56）ng/L、（133.57±18.46）ng/L（均P<0.05）。观察组不良反应率4.26%（2/47）与对照组8.51%（4/47）相比，差异无统计学意义（P>0.05）。结论　金嗓散结胶囊治疗反流性咽喉炎效果显著，可有效改善患者病症，降低炎性因子水平，改善胃肠运动。

关键词: 金嗓散结胶囊, 莫沙必利, 雷贝拉唑, 反流性咽喉炎